We`ve reinvented how biologic drugs are made
Lumen`s patented technology allows us to use the well-known food algae spirulina to deliver therapeutic proteins.

Patented technology with unlimited potential
The astonishingly high cost of traditional drug development meant that using orally delivered biologics to address therapeutic targets in the GI tract and other topical sites wasn’t commercially viable. That’s no longer true. Lumen’s patented biologic drug platform shortens the development process, reduces costs and risks, and accelerates time-to-market, making us the first company to make orally delivered antibody drugs commercially viable.

Formation
Incorporated April 2017

Foundational IP, core team, assets acquired from two predecessor entities

Funding
$84 million in platform investment to date

Intellectual Property
25 issued patents

Issued patents include broad, composition-of-matter claims covering engineered spirulina, recognition that Lumen was the first in the world to engineer spirulina

Broad continuation claims cover all long-term contemplated products

17 other patents pending

Physical Capabilities

60 FTEs, including >25 with MDs, PhDs, and other post-graduate degrees
Fully integrated, on-premise, dedicated cGMP production facility with capacity for several kilograms of drug product per week
Full-time clinical operations and FDA regulatory affairs team
High-throughput strain engineering facility
Advanced protein engineering and optimization
Large-scale AI/machine learning–enabled yield optimization facility
On-premise antibody selection and optimization capabilities (hit to the lead clinic), including advanced in silicoprotein engineering and optimization

A typical biosciences company assembles a group of individuals with a relatively narrow set of skills within a discipline and goes about its business. At Lumen, it’s the particularity of our key scientists’ individual skills and experiences—and the interplay among them—that have been a catalyst to discover and exploit the potential of this new platform organism. As a true platform company, we’re able to create our own portfolio of commercially viable biologic therapies, while establishing a foundation upon which an entirely new generation of scientific discoveries and therapies will be brought to market.

Expertise. Ingenuity. Execution.
We’ve assembled a talented group of leaders with deep expertise in synthetic biology, protein design, immunology, photobioreactor engineering and cell physiology, each with the vision and skills needed to achieve our mission.

Biologic drugs reimagined
Lumen unlocks the full potential of biologic drugs, whose promise has been held back by the lack of scalable technology. Our goal is to transform the way such drugs are developed, what they cost, and who has access to them.

Unrivaled speed, safety, and effectiveness
Our patented technology allows us to develop biologic drugs faster and with lower cost and risk than traditional methods.

Neglected no more
Many highly prevalent diseases have proven impossible to treat with traditional drug-making tools, despite decades of research, so they’ve been essentially abandoned by drug makers. Lumen’s unique technology is ideally suited to finally address these indications.

Lumen Bioscience, Inc. Downloads

Contact supplier